Johnson & Johnson
JNJ
$257.77
+0.31%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). As a healthcare titan, it holds a unique competitive position with a broad portfolio spanning immunology, oncology, neurology, and surgical technologies, underpinned by a strong brand and global distribution. The current investor narrative centers on the company's post-Kenvue divestiture transformation, pipeline momentum from recent acquisitions like Firefly Bio, and the successful Phase 2/3 trial for IMAAVY in rare blood disorders, which are driving optimism around its $50 billion revenue growth target. However, headwinds from Stelara sales erosion and a rotation into defensive sectors amid AI-led market volatility are creating debate about near-term growth sustainability.…
JNJ
Johnson & Johnson
$257.77
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating: Buy. JNJ offers a compelling combination of defensive stability, pipeline-driven growth, and attractive valuation, making it a core holding for long-term investors. The analyst consensus is bullish, with multiple Outperform ratings, though specific price targets are not provided.
Supporting evidence: (1) Trailing P/E of 18.82x is a 14% discount to the industry median of ~22x. (2) Revenue grew 9.08% YoY in Q4 2025, with Innovative Medicine leading. (3) Gross margin expanded to 86.4% from 68.3% a year ago, driving operating margin to 21.9%. (4) TTM free cash flow of $19.7B supports a 2.46% dividend yield and investment in pipeline. The stock is undervalued relative to peers and its own history.
Risks & Conditions: The biggest risks are Stelara erosion and pipeline execution. This Buy rating would be downgraded to Hold if revenue growth falls below 5% for two consecutive quarters, or if the forward P/E exceeds 22x without corresponding earnings acceleration. Upgrade to Strong Buy if IMAAVY receives FDA approval and shows blockbuster potential. Overall, JNJ is undervalued relative to its history and peers, offering a margin of safety.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ is well-positioned for 12-month outperformance given its defensive characteristics, attractive valuation, and pipeline catalysts. The base case of 5-7% growth and stable multiples supports a target of $260-$280, offering modest upside from current levels. The bull case, driven by pipeline success and continued rotation, could push the stock to $280-$300. However, Stelara erosion and execution risk temper confidence, making this a medium-conviction bullish stance. Upgrades would come from positive IMAAVY data or accelerated revenue growth; downgrades from Stelara decline exceeding expectations.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $335.10 and implied upside of +30.0% versus the current price.
Average Target
$335.10
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$206 - $335
Analyst target range
Johnson & Johnson is covered by 15 analysts, with a consensus leaning bullish: recent ratings include Outperform from RBC Capital, Buy from HSBC and Citigroup, and Overweight from Morgan Stanley, while Barclays and JP Morgan maintain Neutral/Equal Weight. The average EPS estimate for the current fiscal year is $17.52, with a range of $17.17 to $17.83, and average revenue estimate of $133.03 billion. While specific price targets are not provided, the consensus recommendation implies a positive outlook. The absence of explicit price targets in the data limits the ability to calculate upside/downside, but the analyst sentiment is clearly constructive. The range of EPS estimates ($17.17–$17.83) is relatively tight, indicating moderate conviction among analysts. The high estimate of $17.83 likely assumes successful pipeline execution and margin expansion, while the low estimate of $17.17 may factor in Stelara erosion and competitive pressures. Recent upgrades from Morgan Stanley (Overweight from Equal Weight) and maintained Buy ratings from multiple firms suggest a positive trend in analyst sentiment. The wide range of institutional actions (from Hold to Outperform) reflects some uncertainty, but the overall tone is favorable.
Bulls vs Bears: JNJ Investment Factors
Johnson & Johnson presents a balanced risk/reward profile. The bull case is supported by strong revenue growth, expanding margins, a robust pipeline (IMAAVY, Firefly Bio), and a defensive low-beta profile that has attracted investors during market rotation. The bear case centers on Stelara patent loss, decelerating growth, and a forward P/E that may not fully account for near-term headwinds. Currently, the bull case has slightly stronger evidence given the valuation discount and pipeline momentum, but the key tension is whether pipeline assets can offset Stelara erosion quickly enough to sustain growth above 5%.
Bullish
- Strong Revenue Growth and Pipeline: Q4 2025 revenue grew 9.08% YoY to $24.56B, driven by Innovative Medicine and MedTech. The successful Phase 2/3 trial for IMAAVY and the $1B Firefly Bio acquisition bolster the pipeline, supporting the $50B revenue target.
- Expanding Margins and Profitability: Gross margin improved to 86.4% in Q4 2025 from 68.3% a year ago, while operating margin rose to 21.9% from 17.1%. Net margin of 20.8% and TTM free cash flow of $19.7B underscore strong cash generation.
- Attractive Valuation vs. Peers and History: Trailing P/E of 18.82x is a 14% discount to the industry median of ~22x and near the low end of its 5-year range (16x-25x), suggesting a margin of safety if pipeline delivers upside.
- Defensive Characteristics and Low Volatility: Beta of 0.235 indicates significantly lower volatility than the market. The stock has outperformed the S&P 500 by 42.3% over the past year, benefiting from rotation into defensive sectors amid AI-led market turbulence.
Bearish
- Stelara Patent Loss Headwind: Stelara sales declined sharply in Q1 2026, overshadowing solid results. As a key revenue driver, its erosion will pressure near-term growth until pipeline assets like IMAAVY ramp up.
- Decelerating Revenue Growth Trend: Revenue growth slowed from 10.5% YoY in Q3 2025 to 9.1% in Q4 2025, and Q1 2025 growth was only 2.4%. The deceleration may continue as Stelara headwinds intensify.
- Elevated Forward P/E Relative to Growth: Forward P/E of 20.16x is above the trailing multiple, implying modest earnings growth expectations. With mid-single-digit revenue growth, the valuation may be stretched if pipeline fails to accelerate.
- Analyst Uncertainty and Mixed Ratings: While consensus is bullish, ratings range from Hold to Outperform, reflecting uncertainty about Stelara erosion and pipeline timing. The tight EPS estimate range ($17.17-$17.83) suggests low conviction.
JNJ Technical Analysis
Johnson & Johnson is in a sustained uptrend, with the stock up 62.97% over the past year, significantly outperforming the S&P 500's 20.63% gain. The current price of $256.98 sits at 95.4% of its 52-week range ($154.80–$269.43), indicating the stock is near its highs and reflecting strong bullish momentum. This positioning near the top of the range suggests the market is pricing in continued positive catalysts, though it also raises the risk of short-term overextension. Over the past month, JNJ has gained 7.75%, while the 3-month change is 7.77%, showing steady short-term momentum that aligns with the longer-term uptrend. The 1-month relative strength of 3.68% versus the S&P 500 indicates the stock is outperforming the market in the near term, while the 1-year relative strength of 42.34% underscores its exceptional long-term relative performance. The stock's beta of 0.235 is very low, meaning it is significantly less volatile than the broader market—a key attribute for risk-averse investors. The 52-week high of $269.43 acts as a resistance level; a breakout above that could signal further upside, while the 52-week low of $154.80 provides a strong support floor. Given the low beta, JNJ is a defensive holding that tends to hold up better during market downturns, which is consistent with recent rotation into defensive sectors.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$155-$269
Price range past year
Annual Return
+64.3%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +1.0% |
| 3m | +7.4% | +7.9% |
| 6m | +17.9% | +8.5% |
| 1y | +64.3% | +20.1% |
| ytd | +24.3% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth is solid but decelerating: the most recent quarter (Q4 2025) reported revenue of $24.564 billion, up 9.08% year-over-year, driven by Innovative Medicine ($15.763 billion) and MedTech ($8.801 billion). However, the multi-quarter trend shows growth slowing from the 10.5% YoY increase in Q3 2025 to the 9.1% in Q4, and the Q1 2025 revenue of $21.893 billion was only 2.4% above the prior year's Q1. The Stelara patent loss is a known headwind, but the pipeline, including IMAAVY and the Firefly Bio acquisition, is expected to reaccelerate growth. Profitability remains robust: net income for Q4 2025 was $5.116 billion, with a net margin of 20.8%, while the trailing twelve-month free cash flow reached $19.698 billion. Gross margin expanded to 86.4% in Q4 2025, up from 68.3% in Q4 2024, reflecting a favorable mix shift toward higher-margin pharmaceuticals. Operating margin improved to 21.9% from 17.1% a year ago, indicating strong cost discipline and operating leverage. The balance sheet is healthy: debt-to-equity is a conservative 0.59, and the current ratio of 1.03 suggests adequate liquidity. Free cash flow generation is strong, with a TTM FCF of $19.7 billion, providing ample capacity for dividends, acquisitions, and debt reduction. Return on equity (ROE) stands at 32.9%, reflecting efficient capital allocation and high profitability.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+9.08%
YoY Comparison
Gross Margin
86.37%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 18.82x, while the forward P/E is 20.16x, implying the market expects earnings growth in the coming year. The gap between trailing and forward P/E suggests modest growth expectations, consistent with the company's mid-single-digit revenue growth trajectory. Compared to the industry average (Drug Manufacturers - General), JNJ's trailing P/E of 18.82x is at a discount to the sector median of approximately 22x, representing a 14% discount. This discount may be justified by slower near-term growth due to Stelara headwinds, but it also presents a value opportunity given the company's strong pipeline and defensive characteristics. Historically, JNJ's trailing P/E has ranged from roughly 16x to 25x over the past five years. The current 18.82x is near the lower end of that range, suggesting the stock is not overvalued relative to its own history. This low historical valuation implies that the market is pricing in conservative expectations, which could provide a margin of safety if the pipeline delivers upside.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's debt-to-equity of 0.59 is conservative, but the current ratio of 1.03 indicates tight liquidity. The Stelara patent loss is a significant operational risk, as the drug's sales decline could pressure revenue growth below 5% in the near term. Free cash flow of $19.7B TTM provides a buffer, but margin expansion may be limited if R&D spending (e.g., $4.25B in Q4 2025) continues to rise to support pipeline development.
Market & Competitive Risks: With a beta of 0.235, JNJ is less sensitive to macro swings, but its defensive premium could compress if risk appetite returns. The stock trades near its 52-week high ($269.43), leaving limited upside if growth disappoints. Competitive threats include biosimilars to Stelara and pipeline failures; the recent Biogen acquisition of RayThera signals increased competition in immunology. Regulatory risks include drug pricing pressures and FDA approval timelines for IMAAVY.
Worst-Case Scenario: If Stelara erosion accelerates and pipeline assets (IMAAVY, Firefly Bio) fail to gain traction, revenue growth could stall or decline. Combined with a multiple contraction to the 5-year low of 16x, the stock could fall to the 52-week low of $154.80, representing a -39.8% decline from the current price of $256.98. This scenario assumes a recession or sector rotation out of healthcare.
FAQ
The key risks are: (1) Stelara patent loss—sales declined sharply in Q1 2026, and further erosion could pressure revenue growth below 5%. (2) Pipeline execution—IMAAVY and Firefly Bio must deliver to offset Stelara; any trial failure would be a setback. (3) Valuation compression—if interest rates rise or risk appetite returns, the defensive premium could shrink, compressing the P/E multiple. (4) Regulatory and litigation risks—drug pricing policies and ongoing talc lawsuits could create overhangs. The most severe risk is a -39.8% decline to the 52-week low of $154.80 if multiple risks materialize.
The 12-month forecast is moderately bullish. The base case (55% probability) targets $260-$280, assuming 5-7% revenue growth and stable multiples. The bull case (25% probability) targets $280-$300, driven by pipeline success and continued rotation into defensives. The bear case (20% probability) targets $200-$230 if Stelara erosion accelerates and pipeline disappoints. The most likely scenario is the base case, with gradual growth and modest upside from current levels.
JNJ is undervalued relative to its peers and its own history. The trailing P/E of 18.82x is below the industry median of ~22x and near the low end of its 5-year range (16x-25x). The forward P/E of 20.16x implies modest growth expectations, which are reasonable given Stelara headwinds. The market is pricing in conservative assumptions, providing a margin of safety if pipeline assets deliver. Compared to the S&P 500's P/E of ~24x, JNJ offers a defensive value proposition.
Yes, JNJ is a good buy for long-term investors seeking a defensive healthcare stock with a reasonable valuation. The trailing P/E of 18.82x is a 14% discount to the industry median, and the stock offers a 2.46% dividend yield backed by $19.7B in TTM free cash flow. The primary risk is Stelara patent loss, but the pipeline (IMAAVY, Firefly Bio) provides upside. For growth-oriented investors, the near-term headwinds may limit upside, but for value and income investors, the current price offers an attractive entry point.
JNJ is best suited for long-term investment (3+ years) due to its defensive nature, low beta of 0.235, and reliable dividend income. Short-term trading may be limited by low volatility and the stock's nearness to its 52-week high. The company's strong cash flows and pipeline provide visibility for sustained growth, making it a core holding for long-term portfolios. A minimum holding period of 3-5 years is recommended to ride out Stelara headwinds and benefit from pipeline maturation.